GPT and metabolic dysfunction-associated steatotic liver disease: The robustness of this study was tested with a set of sensitivity analyses (target independent variable transformation, subgroup analysis, using a GAM to insert the continuity covariate into the equation as a curve, calculating E-values to explore the potential for unmeasured confounding, and reanalyzing the association between the SUA/Scr ratio and NAFLD in participants with normal and impaired kidney function, after excluding participants with FPG > 6.1 mmol/L, or ALT > 40U/L) to ensure the reliability of the results.